文献速递会诊联络精神医学老年精神

既往神经精神疾病与重症COVID-19及其他急性呼吸道感染风险

Preexisting Neuropsychiatric Conditions and Associated Risk of Severe COVID-19 Infection and Other Acute Respiratory Infections.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

基于英国QResearch初级保健数据库的纵向队列研究,纳入大流行前队列11 134 789名成人和当代队列8 388 956名成人,分析既往神经精神疾病诊断和/或治疗与重症COVID-19及其他严重急性呼吸道感染(SARI)结局的关联。结果显示,除痴呆外,既往神经精神疾病诊断和/或治疗与SARI和COVID-19重症结局风险增加相似相关;痴呆与COVID-19重症结局的关联强于SARI。

要点

  • 焦虑诊断与SARI重症(HR 1.16,99%CI 1.13-1.18)和COVID-19重症(HR 1.16,99%CI 1.12-1.20)风险增加相关。
  • 精神病性障碍诊断和治疗与SARI重症(HR 2.56,99%CI 2.40-2.72)和COVID-19重症(HR 2.37,99%CI 2.20-2.55)风险增加相关。
  • 痴呆与COVID-19重症的关联(HR 2.85,99%CI 2.71-3.00)强于SARI(HR 2.13,99%CI 2.07-2.19)。

核心结论

  • 除痴呆外,既往神经精神疾病诊断和/或治疗与COVID-19和其他SARI重症结局风险增加相似相关。
  • 痴呆与COVID-19重症结局的关联强于其他SARI。

研究设计与样本

  • 基于英国QResearch初级保健数据库的纵向队列研究,包括大流行前(2015-2020)和当代(2020-2021)队列。
  • 大流行前队列纳入11 134 789名成人,中位年龄42岁(IQR 29-58),女性占50.7%。
  • 当代队列纳入8 388 956名成人,中位年龄48岁(IQR 34-63),男性占50.2%。
  • 使用柔性参数生存模型估计调整后风险比(HR)及99%置信区间(CI),按初级保健诊所聚类。

主要发现

  • 焦虑诊断与SARI重症风险增加相关(HR 1.16,99%CI 1.13-1.18),与COVID-19重症风险增加相关(HR 1.16,99%CI 1.12-1.20)。
  • 精神病性障碍诊断和治疗与SARI重症风险增加相关(HR 2.56,99%CI 2.40-2.72),与COVID-19重症风险增加相关(HR 2.37,99%CI 2.20-2.55)。
  • 痴呆与COVID-19重症风险的关联(HR 2.85,99%CI 2.71-3.00)高于SARI(HR 2.13,99%CI 2.07-2.19)。

临床怎么用

  • 对既往有焦虑、精神病性障碍等神经精神疾病诊断和/或治疗的患者,应认识到其发生COVID-19和其他SARI重症结局的风险增加。
  • 痴呆患者感染COVID-19时重症风险尤其突出,需加强监测和预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence indicates that preexisting neuropsychiatric conditions confer increased risks of severe outcomes from COVID-19 infection. It is unclear how this increased risk compares with risks associated with other severe acute respiratory infections (SARIs). OBJECTIVE: To determine whether preexisting diagnosis of and/or treatment for a neuropsychiatric condition is associated with severe outcomes from COVID-19 infection and other SARIs and whether any observed association is similar between the 2 outcomes. DESIGN, SETTING, AND PARTICIPANTS: Prepandemic (2015-2020) and contemporary (2020-2021) longitudinal cohorts were derived from the QResearch database of English primary care records. Adjusted hazard ratios (HRs) with 99% CIs were estimated in April 2022 using flexible parametric survival models clustered by primary care clinic. This study included a population-based sample, including all adults in the database who had been registered with a primary care clinic for at least 1 year. Analysis of routinely collected primary care electronic medical records was performed. EXPOSURES: Diagnosis of and/or medication for anxiety, mood, or psychotic disorders and diagnosis of dementia, depression, schizophrenia, or bipolar disorder. MAIN OUTCOMES AND MEASURES: COVID-19-related mortality, or hospital or intensive care unit admission; SARI-related mortality, or hospital or intensive care unit admission. RESULTS: The prepandemic cohort comprised 11 134 789 adults (223 569 SARI cases [2.0%]) with a median (IQR) age of 42 (29-58) years, of which 5 644 525 (50.7%) were female. The contemporary cohort comprised 8 388 956 adults (58 203 severe COVID-19 cases [0.7%]) with a median (IQR) age of 48 (34-63) years, of which 4 207 192 were male (50.2%). Diagnosis and/or treatment for neuropsychiatric conditions other than dementia was associated with an increased likelihood of a severe outcome from SARI (anxiety diagnosis: HR, 1.16; 99% CI, 1.13-1.18; psychotic disorder diagnosis and treatment: HR, 2.56; 99% CI, 2.40-2.72) and COVID-19 (anxiety diagnosis: HR, 1.16; 99% CI, 1.12-1.20; psychotic disorder treatment: HR, 2.37; 99% CI, 2.20-2.55). The effect estimate for severe outcome with dementia was higher for those with COVID-19 than SARI (HR, 2.85; 99% CI, 2.71-3.00 vs HR, 2.13; 99% CI, 2.07-2.19). CONCLUSIONS AND RELEVANCE: In this longitudinal cohort study, UK patients with preexisting neuropsychiatric conditions and treatments were associated with similarly increased risks of severe outcome from COVID-19 infection and SARIs, except for dementia.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ranger TA, Clift AK, Patone M, et al. Preexisting Neuropsychiatric Conditions and Associated Risk of Severe COVID-19 Infection and Other Acute Respiratory Infections. JAMA Psychiatry. 2023. PMID: 36350602. doi:10.1001/jamapsychiatry.2022.3614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。